Physician profile
Rigved V Tadwalkar
NPI 1679885883
$128,987.39
in general payments reported to CMS, 2019-2025
41 companies · $42K in 2025
The $42K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,393 · 2020: $283 · 2021: $1,275 · 2022: $1,399 · 2023: $11K · 2024: $71K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $78K · Honoraria: $26K · Food and Beverage: $10K · Consulting Fee: $5,545 · Travel and Lodging: $4,809 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,037.65 |
| Honoraria | $25,700.00 |
| Food and Beverage | $10,422.44 |
| Consulting Fee | $5,545.02 |
| Travel and Lodging | $4,809.29 |
| Education | $122.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $58,750.13 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $34,764.13 | 2024 | Arcalyst |
| Amgen INC. | $21,100.22 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $7,920.64 | 2019-2025 | Leqvio |
| Janssen Pharmaceuticals, INC | $1,054.19 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $635.40 | 2019-2025 | Wainua, Farxiga, Brilinta |
| Abbott Laboratories | $632.89 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $609.09 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $542.85 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $328.06 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $247.77 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $242.61 | 2021-2025 | Nexletol |
| Pfizer INC. | $215.60 | 2020-2025 | |
| Akcea Therapeutics, INC. | $205.65 | 2019-2020 | |
| Kiniksa Pharmaceuticals, Ltd. | $202.75 | 2022-2023 | Arcalyst |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $167.64 | 2019-2025 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $150.38 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $129.67 | 2019-2025 | Evkeeza |
| Heartflow, INC. | $116.51 | 2022-2025 | Ffrct |
| Irhythm Technologies, INC. | $114.84 | 2022-2023 | Zio Xt Patch |
| Boston Scientific Corporation | $112.17 | 2022-2025 | Watchman Access System, Watchman |
| Lilly USA, LLC | $69.32 | 2024-2025 | Zepbound |
| Biosense Webster, INC. | $64.79 | 2024 | Nuvision Ice Catheter |
| Bridgebio Pharma, INC. | $62.30 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $59.16 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.90 | 2023-2025 | Lifevest |
| Edwards Lifesciences Corporation | $58.37 | 2019 | |
| Sanofi-Aventis U.S. LLC | $54.72 | 2019 | |
| Abiomed | $44.96 | 2025 | |
| Bardy Diagnostics, INC. | $37.26 | 2020-2022 | |
| Cathworks, INC. | $29.34 | 2019 | |
| Sanofi Pasteur INC. | $26.26 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.96 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $23.93 | 2024 | Opsumit, Uptravi |
| Kestra Medical Technology Services, INC. | $21.47 | 2025 | Assure Wcd |
| Recor Medical INC | $20.76 | 2024 | Paradise Renal Denervation System |
| Electromed, INC. | $18.28 | 2025 | Smartvest |
| Itamar Medical INC | $18.24 | 2024 | Watchpatone |
| Idorsia Pharmaceuticals US INC | $17.87 | 2025 | Tryvio |
| Teleflex LLC | $17.79 | 2025 | Guideliner |
| Baxter Healthcare | $15.52 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rigved Tadwalkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.